Trillium and Biogen Idec Enter Into Global License Agreement

TORONTO, January 12 - Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing
innovative immune-based biologics, today announced that it has entered into a
definitive license agreement with Biogen Idec (NASDAQ: BIIB), granting the
latter exclusive worldwide rights to one of Trillium's development programs.

"Biogen Idec is a premier biotechnology partner and a world leader in
immunology research and development", commented Trillium CEO, Dr. Niclas
Stiernholm. "We have had the privilege and fortune to work with some of the
world's best immunology companies over the past few years, which reinforces
the value and quality of our strong and innovative science."

"The Biogen Idec partnership clearly adds value and strongly validates
the quality of our programs" underlined Luc Marengère, lead investor and
Managing General Partner with VG Partners.

Under the terms of the agreement, TTI will receive an upfront payment and
is eligible to receive milestone payments based on achievements of specified
clinical, regulatory and commercial accomplishments. TTI will also receive
royalties on global product sales. No other financial terms were disclosed.
Biogen Idec will be solely responsible for clinical development, regulatory
approvals, manufacturing and commercialization.

"Trillium's strong immunology foundation and its close connection to
Toronto's world class immunology research community, has allowed it to build
a suite of exciting biologies opportunities in the immunoregulatory field",
added Dr. Michael Moore, Trillium's Chairman. "We look forward to concluding
additional partnerships later in the year, particularly around our non-core
assets."

About Trillium:

Trillium Therapeutics Inc. is a private biopharmaceutical company
specializing in innovative therapies of immune-mediated conditions, such as
autoimmune and inflammatory disorders, as well as cancer. The company's lead
program, TTI-1612, is a recombinant growth factor that is being developed for
the treatment of interstitial cystitis (IC) and the prevention of necrotizing
enterocolitis (NEC). Trillium has broad portfolio preclinical immunology
programs, including two that target the CD200 immunoregulatory axis; a
CD200-specific monoclonal antibody for the treatment of cancer, and a CD200Fc
fusion protein for the treatment of autoimmune and inflammatory diseases. In
addition, the company has an FcyRlla-specific humanized monoclonal antibody in
development for treatment of immune complex-mediated inflammatory diseases.

The company has a broad network of external academic and industry R&D
collaborations, including several license agreements with major US
biotechnology companies. The Company is supported by three premier venture
capital investors: Vengrowth Private Equity Partners, Growthworks Capital and
BDC Capital.

For further information: Niclas Stiernholm, Ph.D., Chief Executive
Officer, Trillium Therapeutics Inc., 96 Skyway Avenue, Toronto, Ontario, M9W
4Y9, Canada, Tel: +1-(416)-595-0627, Fax: +1-(416)-595-5835,
niclas@trilliumtherapeutics.com; www.trilliumtherapeutics.com/

For further information: Niclas Stiernholm, Ph.D., Chief Executive Officer, Trillium Therapeutics Inc., 96 Skyway Avenue, Toronto, Ontario, M9W 4Y9, Canada, Tel: +1-(416)-595-0627, Fax: +1-(416)-595-5835, niclas at trilliumtherapeutics.com; www.trilliumtherapeutics.com/